The Evolution of Combining Surface Chemistry and MALDI Mass Spectrometry: A Powerful Foundation for High-Throughput Screening
The integration of surface chemistry and MALDI mass spectrometry has proven to be a powerful combination with significant benefits for small molecule drug discovery. Surface chemistry controls specific and non-specific interactions between biological solutions and the surface and enables analytical compatibility through various detection methods, including MALDI mass spectrometry.
In this webinar, we review different surface chemistries utilized for early drug discovery. We then highlight how innovation at the interface of surface chemistry, MALDI mass spectrometry, and biological assays are opening new avenues for value-driven high-throughput screening platforms to accelerate drug discovery programs for even the most challenging targets.
Key Learning Objectives:
- Understand how surface chemistry enhances assay design for small molecule drug discovery
- Explore the advantages of integrating surface chemistries with MALDI mass spectrometry for high-throughput screening
- Recognize the impact on small molecule drug discovery pipelines
Who should attend:
- Researchers who are interested in the new workflows for high-throughput screening
- Scientists who are interested in high-throughput mass spectrometry
- Investigators who are interested in biochemical assay development
Presenter: Zachary Gurard-Levin, Ph.D. (CEO & Founder, Peapod Bio, Inc., Chicago, IL, USA)
Zachary Gurard-Levin, Ph.D. is the Founder and Chief Executive Officer of Peapod Bio, Inc. He brings over two decades of experience in assay and technology development, high-throughput screening, and drug discovery along with a decade of business development, marketing, and sales experience in small and large publicly traded contract research organizations. Throughout his career, he has utilized creativity to develop solutions that have successfully launched over 200 drug discovery programs. Gurard-Levin is a member of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS). He earned a doctorate in chemistry from the University of Chicago and completed a postdoctoral fellowship in chromatin biology and epigenetics at the Institut Curie in Paris, France.
